Analyze Diet
Advances in experimental medicine and biology2023; 1402; 95-105; doi: 10.1007/978-3-031-25588-5_7

Gene Delivery to Chondrocytes.

Abstract: Delivering genes to chondrocytes offers new possibilities both clinically, for treating conditions that affect cartilage, and in the laboratory, for studying the biology of chondrocytes. Advances in gene therapy have created a number of different viral and non-viral vectors for this purpose. These vectors may be deployed in an ex vivo fashion, where chondrocytes are genetically modified outside the body, or by in vivo delivery where the vector is introduced directly into the body; in the case of articular and meniscal cartilage in vivo delivery is typically by intra-articular injection. Ex vivo delivery is favored in strategies for enhancing cartilage repair as these can be piggy-backed on existing cell-based technologies, such as autologous chondrocyte implantation, or used in conjunction with marrow-stimulating techniques such as microfracture. In vivo delivery to articular chondrocytes has proved more difficult, because the dense, anionic, extra-cellular matrix of cartilage limits access to the chondrocytes embedded within it. As Grodzinsky and colleagues have shown, the matrix imposes strict limits on the size and charge of particles able to diffuse through the entire depth of articular cartilage. Empirical observations suggest that the larger viral vectors, such as adenovirus (~100 nm), are unable to transduce chondrocytes in situ following intra-articular injection. However, adeno-associated virus (AAV; ~25 nm) is able to do so in horse joints. AAV is presently in clinical trials for arthritis gene therapy, and it will be interesting to see whether human chondrocytes are also transduced throughout the depth of cartilage by AAV following a single intra-articular injection. Viral vectors have been used to deliver genes to the intervertebral disk but there has been little research on gene transfer to chondrocytes in other cartilaginous tissues such as nasal, auricular or tracheal cartilage.
Publication Date: 2023-04-14 PubMed ID: 37052849PubMed Central: 9274665DOI: 10.1007/978-3-031-25588-5_7Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study explores the possibilities of using gene delivery to treat cartilage-related conditions and to understand the biology of chondrocytes, cells that lie within the cartilage. Advances in gene therapy have made it possible to use different viral and non-viral vectors for gene delivery, either by modifying chondrocytes outside of the body (ex vivo) or by directly introducing them into the body (in vivo).

Gene Delivery Techniques

  • The research identifies two primary methods of gene delivery: ex vivo and in vivo. Ex vivo method involves genetic modification of chondrocytes outside the body, while in vivo involves direct gene introduction within the body, commonly achieved by intra-articular injection for articular and meniscal cartilage.
  • Ex vivo delivery is preferable when enhancing cartilage repair due to its ability to be combined with other cell-based technologies like autologous chondrocyte implantation or marrow-stimulating techniques such as microfracture.
  • In vivo delivery to articular chondrocytes, on the other hand, poses more challenges due to the dense, anionic, extra-cellular matrix of the cartilage which limits access to the embedded chondrocytes. This matrix sets strict conditions on the size and charge of particles that can diffuse through the entire cartilage depth.

Role of Viral Vectors

  • Viral vectors such as the adenovirus and adeno-associated virus (AAV) are employed in gene delivery. Adenovirus, due to its larger size, is unable to transduce chondrocytes following intra-articular injection. On the other hand, AAV, being smaller, has proven capable of achieving this in horse joints.
  • Presently, AAV is being used in clinical trials for arthritis gene therapy. The study aims to see if human chondrocytes would also respond similarly to AAV delivery following a singular intra-articular injection.
  • While viral vectors have been utilized in gene delivery to the intervertebral disk, the study notes a shortage of research on gene transfer to chondrocytes in other cartilaginous tissues like nasal, auricular or tracheal cartilage.

Cite This Article

APA
Nagelli CV, Evans CH, De la Vega RE. (2023). Gene Delivery to Chondrocytes. Adv Exp Med Biol, 1402, 95-105. https://doi.org/10.1007/978-3-031-25588-5_7

Publication

ISSN: 0065-2598
NlmUniqueID: 0121103
Country: United States
Language: English
Volume: 1402
Pages: 95-105

Researcher Affiliations

Nagelli, Christopher V
  • Musculoskeletal Gene Therapy Laboratory, Mayo Clinic, Rochester, MN, USA.
Evans, Christopher H
  • Musculoskeletal Gene Therapy Laboratory, Mayo Clinic, Rochester, MN, USA. Evans.christopher@mayo.edu.
De la Vega, Rodolfo E
  • Musculoskeletal Gene Therapy Laboratory, Mayo Clinic, Rochester, MN, USA.

MeSH Terms

  • Humans
  • Animals
  • Horses
  • Chondrocytes
  • Gene Transfer Techniques
  • Genetic Therapy / methods
  • Cartilage, Articular
  • Injections, Intra-Articular

References

This article includes 53 references
  1. Evans CH, Ghivizzani SC, Robbins PD. Orthopaedic gene therapy: twenty-five years on.. JBJS Rev 9.
    doi: 10.2106/jbjs.rvw.20.00220google scholar: lookup
  2. Watson-Levings RS, Palmer GD, Levings PP, Dacanay EA, Evans CH, Ghivizzani SC. Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation.. Front Bioeng Biotechnol 2022;10:901317.
    pubmed: 35837555pmc: 9274665doi: 10.3389/fbioe.2022.901317google scholar: lookup
  3. Nagelli CV, Evans CH, de la Vega RE. Viral gene delivery in chondrocytes.. .
  4. Lundstrom K. Viral Vectors in Gene Therapy.. Diseases 2018 May 21;6(2).
    pubmed: 29883422pmc: 6023384doi: 10.3390/diseases6020042google scholar: lookup
  5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.. Science 2003 Oct 17;302(5644):415-9.
    pubmed: 14564000doi: 10.1126/science.1088547google scholar: lookup
  6. George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.. N Engl J Med 2021 Nov 18;385(21):1961-1973.
    pubmed: 34788507pmc: 8672712doi: 10.1056/NEJMoa2104205google scholar: lookup
  7. Kreiss P, Cameron B, Rangara R, Mailhe P, Aguerre-Charriol O, Airiau M, Scherman D, Crouzet J, Pitard B. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency.. Nucleic Acids Res 1999 Oct 1;27(19):3792-8.
    pubmed: 10481017pmc: 148641doi: 10.1093/nar/27.19.3792google scholar: lookup
  8. Yin W, Xiang P, Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system.. Anal Biochem 2005 Nov 15;346(2):289-94.
    pubmed: 16213455doi: 10.1016/j.ab.2005.08.029google scholar: lookup
  9. Zu H, Gao D. Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects.. AAPS J 2021 Jun 2;23(4):78.
    pubmed: 34076797doi: 10.1208/s12248-021-00608-7google scholar: lookup
  10. Slivac I, Guay D, Mangion M, Champeil J, Gaillet B. Non-viral nucleic acid delivery methods.. Expert Opin Biol Ther 2017 Jan;17(1):105-118.
    pubmed: 27740858doi: 10.1080/14712598.2017.1248941google scholar: lookup
  11. Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The Limitless Future of RNA Therapeutics.. Front Bioeng Biotechnol 2021;9:628137.
    pubmed: 33816449pmc: 8012680doi: 10.3389/fbioe.2021.628137google scholar: lookup
  12. De La Vega RE, van Griensven M, Zhang W, Coenen MJ, Nagelli CV, Panos JA, Peniche Silva CJ, Geiger J, Plank C, Evans CH, Balmayor ER. Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.. Sci Adv 2022 Feb 18;8(7):eabl6242.
    pubmed: 35171668doi: 10.1126/sciadv.abl6242google scholar: lookup
  13. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration.. Nat Med 1999 Jul;5(7):753-9.
    pubmed: 10395319doi: 10.1038/10473google scholar: lookup
  14. Raisin S, Belamie E, Morille M. Non-viral gene activated matrices for mesenchymal stem cells based tissue engineering of bone and cartilage.. Biomaterials 2016 Oct;104:223-37.
  15. Cam C, Segura T. Matrix-based gene delivery for tissue repair.. Curr Opin Biotechnol 2013 Oct;24(5):855-63.
    pubmed: 23680305pmc: 3770770doi: 10.1016/j.copbio.2013.04.007google scholar: lookup
  16. Kang R, Marui T, Ghivizzani SC, Nita IM, Georgescu HI, Suh JK, Robbins PD, Evans CH. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study.. Osteoarthr Cartil 5:139–143.
  17. Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler BJ. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation.. J Clin Invest 1995 Nov;96(5):2454-60.
    pubmed: 7593634pmc: 185898doi: 10.1172/JCI118303google scholar: lookup
  18. Palmer GD, Gouze E, Gouze JN, Betz OB, Evans CH, Ghivizzani SC. Gene transfer to articular chondrocytes with recombinant adenovirus.. Methods Mol Biol 2003;215:235-46.
    pubmed: 12512303doi: 10.1385/1-59259-345-3:235google scholar: lookup
  19. Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy.. Nat Rev Rheumatol 2014 Jan;10(1):11-22.
    pubmed: 24189839doi: 10.1038/nrrheum.2013.159google scholar: lookup
  20. Evans CH. Catering to chondrocytes.. Sci Transl Med 2018 Nov 28;10(469).
    pubmed: 30487250doi: 10.1126/scitranslmed.aav7043google scholar: lookup
  21. Krishnan Y, Rees HA, Rossitto CP, Kim SE, Hung HK, Frank EH, Olsen BD, Liu DR, Hammond PT, Grodzinsky AJ. Green fluorescent proteins engineered for cartilage-targeted drug delivery: Insights for transport into highly charged avascular tissues.. Biomaterials 2018 Nov;183:218-233.
  22. Bajpayee AG, Wong CR, Bawendi MG, Frank EH, Grodzinsky AJ. Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis.. Biomaterials 2014 Jan;35(1):538-49.
  23. Bajpayee AG, Grodzinsky AJ. Cartilage-targeting drug delivery: can electrostatic interactions help?. Nat Rev Rheumatol 2017 Mar;13(3):183-193.
    pubmed: 28202920doi: 10.1038/nrrheum.2016.210google scholar: lookup
  24. Baragi VM, Renkiewicz RR, Qiu L, Brammer D, Riley JM, Sigler RE, Frenkel SR, Amin A, Abramson SB, Roessler BJ. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo.. Osteoarthr Cartil 5:275–282.
  25. ter Huurne M, Schelbergen R, Blattes R, Blom A, de Munter W, Grevers LC, Jeanson J, Noël D, Casteilla L, Jorgensen C, van den Berg W, van Lent PL. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis.. Arthritis Rheum 2012 Nov;64(11):3604-13.
    pubmed: 22961401doi: 10.1002/art.34626google scholar: lookup
  26. Horie M, Choi H, Lee RH, Reger RL, Ylostalo J, Muneta T, Sekiya I, Prockop DJ. Intra-articular injection of human mesenchymal stem cells (MSCs) promote rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen.. Osteoarthr Cartil 20:1197–1207.
  27. Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, Mabuchi Y, Akazawa C, Kobayashi E, Matsumoto K, Futamura K, Saito T, Sekiya I. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats.. Osteoarthr Cartil 24:1061–1070.
  28. Cucchiarini M, Madry H. Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair.. Nat Rev Rheumatol 2019 Jan;15(1):18-29.
    pubmed: 30514957doi: 10.1038/s41584-018-0125-2google scholar: lookup
  29. Watson Levings RS, Broome TA, Smith AD, Rice BL, Gibbs EP, Myara DA, Hyddmark EV, Nasri E, Zarezadeh A, Levings PP, Lu Y, White ME, Dacanay EA, Foremny GB, Evans CH, Morton AJ, Winter M, Dark MJ, Nickerson DM, Colahan PT, Ghivizzani SC. Gene therapy for osteoarthritis: pharmacokinetics of intra-articular self-complementary adeno-associated virus Interleukin-1 receptor antagonist delivery in an equine model. Hum Gene Ther Clin Dev 29:90–100.
  30. Bajpayee AG, Scheu M, Grodzinsky AJ, Porter RM. A rabbit model demonstrates the influence of cartilage thickness on intra-articular drug delivery and retention within cartilage.. J Orthop Res 2015 May;33(5):660-7.
    pubmed: 25627105doi: 10.1002/jor.22841google scholar: lookup
  31. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, Watkins SC, Herndon JH. Gene transfer to human joints: progress toward a gene therapy of arthritis.. Proc Natl Acad Sci U S A 2005 Jun 14;102(24):8698-703.
    pubmed: 15939878pmc: 1150836doi: 10.1073/pnas.0502854102google scholar: lookup
  32. Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients.. Cytotherapy 2012 Feb;14(2):247-56.
    pubmed: 22242865pmc: 3793276doi: 10.3109/14653249.2011.629645google scholar: lookup
  33. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy is becoming a reality.. Nat Rev Rheumatol 2018 Jul;14(7):381-382.
    pubmed: 29743627doi: 10.1038/s41584-018-0009-5google scholar: lookup
  34. Evans CH. The vicissitudes of gene therapy.. Bone Joint Res 2019 Oct;8(10):469-471.
  35. Goossens PH, Huizinga TW. Adenoviral-mediated gene transfer to the synovial tissue.. Clin Exp Rheumatol 2002 May-Jun;20(3):415-9.
    pubmed: 12102483
  36. Graceffa V, Vinatier C, Guicheux J, Evans CH, Stoddart M, Alini M, Zeugolis DI. State of art and limitations in genetic engineering to induce stable chondrogenic phenotype.. Biotechnol Adv 2018 Nov 15;36(7):1855-1869.
  37. Palmer G, Pascher A, Gouze E, Gouze JN, Betz O, Spector M, Robbins PD, Evans CH, Ghivizzani SC. Development of gene-based therapies for cartilage repair.. Crit Rev Eukaryot Gene Expr 2002;12(4):259-73.
  38. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model.. J Bone Joint Surg Br 2007 May;89(5):672-85.
    pubmed: 17540757doi: 10.1302/0301-620X.89B5.18343google scholar: lookup
  39. Hidaka C, Goodrich LR, Chen CT, Warren RF, Crystal RG, Nixon AJ. Acceleration of cartilage repair by genetically modified chondrocytes over expressing bone morphogenetic protein-7.. J Orthop Res 2003 Jul;21(4):573-83.
    pubmed: 12798054doi: 10.1016/S0736-0266(02)00264-4google scholar: lookup
  40. Ortved KF, Begum L, Mohammed HO, Nixon AJ. Implantation of rAAV5-IGF-I transduced autologous chondrocytes improves cartilage repair in full-thickness defects in the equine model.. Mol Ther 2015 Feb;23(2):363-73.
    pubmed: 25311491doi: 10.1038/mt.2014.198google scholar: lookup
  41. Pascher A, Palmer GD, Steinert A, Oligino T, Gouze E, Gouze JN, Betz O, Spector M, Robbins PD, Evans CH, Ghivizzani SC. Gene delivery to cartilage defects using coagulated bone marrow aspirate.. Gene Ther 2004 Jan;11(2):133-41.
    pubmed: 14712297doi: 10.1038/sj.gt.3302155google scholar: lookup
  42. Palmer GD, Steinert A, Pascher A, Gouze E, Gouze JN, Betz O, Johnstone B, Evans CH, Ghivizzani SC. Gene-induced chondrogenesis of primary mesenchymal stem cells in vitro.. Mol Ther 2005 Aug;12(2):219-28.
    pubmed: 16043093doi: 10.1016/j.ymthe.2005.03.024google scholar: lookup
  43. Steinert AF, Palmer GD, Pilapil C, Nöth U, Evans CH, Ghivizzani SC. Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer.. Tissue Eng Part A 2009 May;15(5):1127-39.
    pubmed: 18826340doi: 10.1089/ten.tea.2007.0252google scholar: lookup
  44. Sieker JT, Kunz M, Weissenberger M, Gilbert F, Frey S, Rudert M, Steinert AF. Direct bone morphogenetic protein 2 and Indian hedgehog gene transfer for articular cartilage repair using bone marrow coagulates.. Osteoarthr Cartil 23:433–442.
  45. Nagelli CV, De La Vega RE, Coenen M, De Padilla CL, Panos JA, Tovar A, Müller SA, Evans CH. Expedited gene delivery for osteochondral defect repair in a rabbit knee model: A one-year investigation.. Osteoarthr Cartil Open 2022 Jun;4(2).
    pubmed: 36338933pmc: 9635382doi: 10.1016/j.ocarto.2022.100257google scholar: lookup
  46. Ivkovic A, Pascher A, Hudetz D, Maticic D, Jelic M, Dickinson S, Loparic M, Haspl M, Windhager R, Pecina M. Articular cartilage repair by genetically modified bone marrow aspirate in sheep.. Gene Ther 2010 Jun;17(6):779-89.
    pubmed: 20220780doi: 10.1038/gt.2010.16google scholar: lookup
  47. Cucchiarini M, Asen AK, Goebel L, Venkatesan JK, Schmitt G, Zurakowski D, Menger MD, Laschke MW, Madry H. Effects of TGF-β Overexpression via rAAV Gene Transfer on the Early Repair Processes in an Osteochondral Defect Model in Minipigs.. Am J Sports Med 2018 Jul;46(8):1987-1996.
    pubmed: 29792508doi: 10.1177/0363546518773709google scholar: lookup
  48. Cucchiarini M, Madry H. Overexpression of human IGF-I via direct rAAV-mediated gene transfer improves the early repair of articular cartilage defects in vivo.. Gene Ther 2014 Sep;21(9):811-9.
    pubmed: 24989812doi: 10.1038/gt.2014.58google scholar: lookup
  49. Cucchiarini M, Orth P, Madry H. Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo.. J Mol Med (Berl) 2013 May;91(5):625-36.
    pubmed: 23149825doi: 10.1007/s00109-012-0978-9google scholar: lookup
  50. Lange C, Madry H, Venkatesan JK, Schmitt G, Speicher-Mentges S, Zurakowski D, Menger MD, Laschke MW, Cucchiarini M. rAAV-Mediated sox9 Overexpression Improves the Repair of Osteochondral Defects in a Clinically Relevant Large Animal Model Over Time In Vivo and Reduces Perifocal Osteoarthritic Changes.. Am J Sports Med 2021 Nov;49(13):3696-3707.
    pubmed: 34643471doi: 10.1177/03635465211049414google scholar: lookup
  51. Morscheid YP, Venkatesan JK, Schmitt G, Orth P, Zurakowski D, Speicher-Mentges S, Menger MD, Laschke MW, Cucchiarini M, Madry H. rAAV-Mediated Human FGF-2 Gene Therapy Enhances Osteochondral Repair in a Clinically Relevant Large Animal Model Over Time In Vivo.. Am J Sports Med 2021 Mar;49(4):958-969.
    pubmed: 33606561doi: 10.1177/0363546521988941google scholar: lookup
  52. Madry H, Venkatesan JK, Carballo-Pedrares N, Rey-Rico A, Cucchiarini M. Scaffold-Mediated Gene Delivery for Osteochondral Repair.. Pharmaceutics 2020 Sep 29;12(10).
    pubmed: 33003607pmc: 7601511doi: 10.3390/pharmaceutics12100930google scholar: lookup
  53. Nishida K, Kang JD, Suh JK, Robbins PD, Evans CH, Gilbertson LG. Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration.. Spine (Phila Pa 1976) 1998 Nov 15;23(22):2437-42; discussion 2443.

Citations

This article has been cited 0 times.